(Q44769550)

6 December 2017

Cost-effectiveness of apixaban compared to warfarin in the management of atrial fibrillation in Australia (English)

1 reference

6 December 2017

0 references

1 reference

1 reference

1 reference

3

1 reference

6 December 2017

Zanfina Ademi

1

0 references

author name string

Kumar Pasupathi

series ordinal

2

1 reference

PubMed ID

24281250

6 December 2017

language of work or name

1 reference

26 November 2013

1 reference

European Journal of Preventive Cardiology

6 December 2017

1 reference

6 December 2017

22

1 reference

6 December 2017

3

1 reference

6 December 2017

344-353

1 reference

Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study

6 December 2017

1 reference

https://api.crossref.org/works/10.1177%2F2047487313514019

Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487313514019

ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiolog

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487313514019

Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487313514019

Why is warfarin underused for stroke prevention in atrial fibrillation? A detailed review of electronic medical records

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487313514019

Apixaban versus warfarin in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487313514019

An introduction to Markov modelling for economic evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487313514019

The cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487313514019

Estimating the long-term costs of ischemic and hemorrhagic stroke for Australia: new evidence derived from the North East Melbourne Stroke Incidence Study (NEMESIS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487313514019

Handling uncertainty in cost-effectiveness models

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487313514019

Review of NICE's recommendations, 1999-2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487313514019

Cost-effectiveness of apixaban compared with warfarin for stroke prevention in atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487313514019

Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487313514019

Dabigatran versus warfarin in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487313514019

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487313514019

Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487313514019

Cost-effectiveness of dabigatran for stroke prevention in non-valvular atrial fibrillation in Spain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487313514019

Cost-effectiveness of dabigatran etexilate for stroke prevention in non-valvular atrial fibrillation. Applying RE-LY to clinical practice in Denmark.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487313514019

Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487313514019

Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487313514019

Systematic review and adjusted indirect comparison meta-analysis of oral anticoagulants in atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487313514019

Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487313514019

Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487313514019

An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487313514019

Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a ‘real world’ atrial fibrillation population: A modelling analysis based on a nationwide cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487313514019

Understanding medication compliance and persistence from an economics perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487313514019

Medication compliance and older people: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487313514019

Drug Prices and Value for Money

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487313514019

A model for undertaking effectiveness and cost-effectiveness analyses of primary preventive strategies in cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487313514019

21 January 2018

Identifiers

DOI

10.1177/2047487313514019

1 reference

release_iw35ll76g5epfo2lvnfpx7onh4

6 December 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/iw35ll76g5epfo2lvnfpx7onh4

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

24281250

1 reference

PubMed ID

24281250